Amyloid β-Protein (1-15) Mechanistic Insights, Clinical Valu

Amyloid β-Protein (1-15): Mechanistic Insights, Clinical Value, and Research Applications in Neurodegenerative Disease
Introduction [Related: Ilomastat]
Amyloid β-protein (Aβ) is a peptide fragment derived from the amyloid precursor protein (APP) through sequential proteolytic cleavage by β- and γ-secretases. Among the various isoforms, the N-terminal fragment Amyloid β-Protein (1-15) (Aβ1-15) has garnered significant attention for its role in the pathogenesis and potential therapeutic targeting of Alzheimer’s disease (AD) and related neurodegenerative disorders. Aβ1-15 is a synthetic peptide corresponding to the first 15 amino acids of the full-length Aβ peptide, which is implicated in amyloid plaque formation, synaptic dysfunction, and neurotoxicity (Haass & Selkoe, 2007, Neuron). [Related: mg132 protease inhibitor]
The mechanism of action of Aβ1-15 is multifaceted. While full-length Aβ peptides (notably Aβ1-40 and Aβ1-42) are known to aggregate and form neurotoxic oligomers and plaques, the shorter Aβ1-15 fragment exhibits distinct biochemical and biological properties. Notably, Aβ1-15 is less prone to aggregation and has been shown to modulate immune responses, influence synaptic plasticity, and interact with cellular receptors differently compared to its longer counterparts (Walsh et al., 2002, Nature). These characteristics make Aβ1-15 a valuable tool for dissecting the molecular underpinnings of amyloidogenic processes and for developing targeted interventions in AD research. [Related: ONX-0914 (PR-957)]
Clinical Value and Applications
The clinical value of Amyloid β-Protein (1-15) lies primarily in its utility as a research reagent for elucidating the molecular mechanisms of amyloid pathology and for screening potential therapeutic agents. Aβ1-15 serves as a model peptide in studies investigating the early events of amyloidogenesis, immune modulation, and synaptic function. Its unique sequence and structural properties enable researchers to differentiate the effects of N-terminal Aβ fragments from those of full-length peptides.
In the context of Alzheimer’s disease, Aβ1-15 has been used to study the immunogenicity of amyloid peptides, as it contains epitopes recognized by both B and T cells (Monsonego et al., 2003, PNAS). This feature is particularly relevant for the development of immunotherapeutic strategies targeting amyloid pathology. Furthermore, Aβ1-15 is employed in the generation of monoclonal antibodies and in the design of peptide-based vaccines aimed at eliciting specific immune responses without inducing adverse effects associated with full-length Aβ immunization (Lambracht-Washington et al., 2011, J. Neuroimmunol.).
Beyond immunological applications, Aβ1-15 is instrumental in studies of synaptic plasticity and neurotoxicity. It has been shown to modulate long-term potentiation (LTP) and long-term depression (LTD) in hippocampal neurons, providing insights into the synaptic dysfunction observed in early AD (Shankar et al., 2007, J. Neurosci.). Additionally, the peptide is utilized in high-throughput screening assays for small molecule inhibitors or antibodies that can modulate Aβ aggregation or toxicity.
Key Challenges and Pain Points Addressed
Current therapeutic approaches for Alzheimer’s disease and related amyloidopathies face several challenges, including limited efficacy, off-target effects, and the risk of inducing autoimmune responses. Full-length Aβ peptides, while central to disease pathology, are highly aggregation-prone and neurotoxic, complicating their use in immunization or as research tools.
Amyloid β-Protein (1-15) addresses several of these pain points:
1. **Reduced Aggregation and Toxicity:** Unlike Aβ1-42, Aβ1-15 does not readily form neurotoxic oligomers or fibrils, making it safer for in vitro and in vivo studies (Walsh et al., 2002, Nature).
2. **Epitope Specificity:** The N-terminal region of Aβ contains immunodominant epitopes, allowing for the generation of antibodies and T cell responses that are specific and less likely to cross-react with endogenous proteins (Monsonego et al., 2003, PNAS).
3. **Facilitating Mechanistic Studies:** Aβ1-15 enables the dissection of N-terminal-specific functions and interactions, which are often masked in studies using full-length peptides.
4. **Vaccine Development:** The use of Aβ1-15 in vaccine formulations reduces the risk of adverse inflammatory responses, as observed in clinical trials with full-length Aβ vaccines (Lambracht-Washington et al., 2011, J. Neuroimmunol.).
Literature Review
A substantial body of literature supports the utility and significance of Amyloid β-Protein (1-15) in neurodegenerative disease research:
1. **Haass & Selkoe (2007, Neuron):** This seminal review outlines the generation, aggregation, and toxicity of Aβ peptides, highlighting the differential properties of N-terminal fragments such as Aβ1-15 in amyloidogenesis.
2. **Walsh et al. (2002, Nature):** The authors demonstrate that synthetic Aβ1-15 does not form toxic oligomers, in contrast to longer Aβ peptides, and can modulate synaptic function without inducing cell death.
3. **Monsonego et al. (2003, PNAS):** This study identifies Aβ1-15 as a key immunogenic fragment, capable of eliciting T cell responses in both mice and humans, and underscores its relevance in immunotherapy development.
4. **Lambracht-Washington et al. (2011, J. Neuroimmunol.):** The authors report that vaccination with Aβ1-15 induces robust antibody responses without the adverse effects associated with full-length Aβ immunization, supporting its use in vaccine design.
5. **Shankar et al. (2007, J. Neurosci.):** This work explores the impact of Aβ fragments on synaptic plasticity, revealing that Aβ1-15 modulates LTP and LTD differently from full-length peptides.
6. **Kim et al. (2015, Exp. Mol. Med.):** The study investigates the interaction of Aβ1-15 with microglial receptors, demonstrating its role in modulating neuroinflammation.
7. **Bayer et al. (2001, J. Biol. Chem.):** The authors characterize the structural properties of Aβ1-15 and its interactions with cellular membranes, providing a basis for understanding its reduced aggregation propensity.
Experimental Data and Results
Experimental investigations using Amyloid β-Protein (1-15) have yielded several important findings:
- **Aggregation and Toxicity:** In vitro assays reveal that Aβ1-15 remains predominantly monomeric under physiological conditions, with negligible formation of β-sheet-rich aggregates (Walsh et al., 2002, Nature). Cell viability assays in primary neuronal cultures indicate that Aβ1-15 does not induce significant cytotoxicity, in contrast to Aβ1-42, which causes marked cell death at comparable concentrations.
- **Immunogenicity:** Immunization studies in transgenic mouse models of AD demonstrate that Aβ1-15 elicits strong humoral and cellular immune responses. Notably, vaccinated animals exhibit reduced amyloid plaque burden and improved cognitive performance, without evidence of meningoencephalitis or other inflammatory complications (Lambracht-Washington et al., 2011, J. Neuroimmunol.).
- **Synaptic Function:** Electrophysiological recordings from hippocampal slices treated with Aβ1-15 show modulation of synaptic plasticity, with effects on both LTP and LTD. These findings suggest a role for Aβ1-15 in the regulation of synaptic signaling pathways (Shankar et al., 2007, J. Neurosci.).
- **Microglial Activation:** Exposure of microglial cultures to Aβ1-15 results in altered cytokine production and phagocytic activity, implicating this fragment in the modulation of neuroinflammatory responses (Kim et al., 2015, Exp. Mol. Med.).
Collectively, these data underscore the utility of Aβ1-15 as a research tool for dissecting the molecular and cellular mechanisms underlying amyloid pathology and for evaluating the efficacy of candidate therapeutics.
Usage Guidelines and Best Practices
The effective use of Amyloid β-Protein (1-15) in research applications requires careful consideration of several factors:
- **Peptide Preparation:** Aβ1-15 should be reconstituted in sterile, endotoxin-free water or buffer at the recommended concentration (typically 1–5 mg/mL). Aliquots should be stored at –20°C to –80°C to prevent degradation and repeated freeze-thaw cycles.
- **Experimental Controls:** When using Aβ1-15 in cell-based or animal studies, appropriate controls (e.g., vehicle-treated, scrambled peptide) should be included to account for non-specific effects.
- **Concentration and Exposure Time:** Optimal concentrations and incubation times should be empirically determined for each experimental system. In vitro studies commonly use concentrations ranging Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 22 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11581775